Mei Ri Jing Ji Xin Wen·2025-09-15 08:57Company Highlights -药捷安康, a biopharmaceutical company focused on innovative therapies for cancer, inflammation, and cardiovascular metabolic diseases, has recently been added to the Hong Kong Stock Connect list, allowing southbound funds to invest in its shares [4] - On September 10,药捷安康 announced that its core product, Tinengotinib (TT-00420), received clinical approval from the National Medical Products Administration of China for a Phase II trial in treating HR+/HER2- recurrent or metastatic breast cancer [4][6] - The stock of药捷安康 surged by 115% on the day, reaching a peak price of 431.4 HKD, and has increased over 30 times since its IPO price of 13.15 HKD, with a market capitalization exceeding 120 billion HKD [5] Industry Insights - 宁德时代 (CATL) saw its A-shares rise by 14%, reaching a historical high of 371.52 HKD, while its H-shares also hit a new high of 476.8 HKD, closing at 465 HKD with a 7.44% increase [6] - According to Pacific Securities, 宁德时代 maintains a leading global market share with a gross margin of 25.58% in the first half of 2025, supported by steady production growth and an expanding product matrix [7] - The report indicates that 宁德时代's battery system capacity reached 345 GWh, with an additional 235 GWh under construction, positioning the company well to meet customer demand [7] Market Trends - The Hong Kong stock market experienced a slight upward trend, with the Hang Seng Index closing at 26,446.56 points, up 0.22%, and the Hang Seng Tech Index rising by 0.91% [2] - Southbound funds continued to show strong buying interest, with a net purchase amount exceeding 14 billion HKD on the first trading day of the week [9] - The market outlook suggests that the Hong Kong stock market may perform strongly following the Federal Reserve's potential interest rate cuts, with historical data indicating an average increase of 35.4% in the Hang Seng Index over the following 12 months [11]